KR20150125728A - 캡슐화된 피코플라틴 - Google Patents

캡슐화된 피코플라틴 Download PDF

Info

Publication number
KR20150125728A
KR20150125728A KR1020157030498A KR20157030498A KR20150125728A KR 20150125728 A KR20150125728 A KR 20150125728A KR 1020157030498 A KR1020157030498 A KR 1020157030498A KR 20157030498 A KR20157030498 A KR 20157030498A KR 20150125728 A KR20150125728 A KR 20150125728A
Authority
KR
South Korea
Prior art keywords
picoplatin
water
cancer
dosage form
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157030498A
Other languages
English (en)
Korean (ko)
Inventor
알리스테어 제이. 레이
크리스토퍼 에이. 프로키신
엔젤리카 필립스
헤이젤 비. 브라이츠
Original Assignee
포니아드 파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포니아드 파마슈티칼즈, 인크. filed Critical 포니아드 파마슈티칼즈, 인크.
Publication of KR20150125728A publication Critical patent/KR20150125728A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020157030498A 2007-02-09 2008-02-08 캡슐화된 피코플라틴 Ceased KR20150125728A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US88920107P 2007-02-09 2007-02-09
US60/889,201 2007-02-09
US88967507P 2007-02-13 2007-02-13
US60/889,675 2007-02-13
US98415607P 2007-10-31 2007-10-31
US60/984,156 2007-10-31
US98902007P 2007-11-19 2007-11-19
US60/989,020 2007-11-19
PCT/US2008/001746 WO2008097658A1 (en) 2007-02-09 2008-02-08 Encapsulated picoplatin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097018781A Division KR20090109130A (ko) 2007-02-09 2008-02-08 캡슐화된 피코플라틴

Publications (1)

Publication Number Publication Date
KR20150125728A true KR20150125728A (ko) 2015-11-09

Family

ID=39682045

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157030498A Ceased KR20150125728A (ko) 2007-02-09 2008-02-08 캡슐화된 피코플라틴
KR1020097018781A Ceased KR20090109130A (ko) 2007-02-09 2008-02-08 캡슐화된 피코플라틴

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097018781A Ceased KR20090109130A (ko) 2007-02-09 2008-02-08 캡슐화된 피코플라틴

Country Status (12)

Country Link
US (2) US20100062056A1 (enExample)
EP (1) EP2109451A4 (enExample)
JP (1) JP2010518088A (enExample)
KR (2) KR20150125728A (enExample)
CN (1) CN101663040A (enExample)
AU (1) AU2008214199A1 (enExample)
BR (1) BRPI0806362A2 (enExample)
CA (1) CA2677639A1 (enExample)
IL (1) IL200261A0 (enExample)
MX (1) MX2009008487A (enExample)
RU (1) RU2009133447A (enExample)
WO (1) WO2008097658A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2249644A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER
WO2010120336A1 (en) * 2009-04-15 2010-10-21 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
JP2657393B2 (ja) * 1988-05-18 1997-09-24 日本化薬株式会社 化学塞栓療法剤
CN1071570C (zh) * 1993-06-14 2001-09-26 詹森药业有限公司 阿司咪唑和假麻黄碱的缓释薄膜包衣片
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
DE19847618A1 (de) * 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
US20060128762A1 (en) * 2002-09-06 2006-06-15 D.Western Therapeutics Institute Medicinal composition and method for treating malignant tumor and utilization thereof
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
PL1720540T3 (pl) * 2004-02-18 2008-11-28 Gpc Biotech Ag Satraplatyna do leczenia odpornych i opornych nowotworów
US9061015B2 (en) * 2004-12-30 2015-06-23 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
WO2006090931A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) * 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US7687487B2 (en) * 2007-04-19 2010-03-30 Bionumerik Pharmaceuticals, Inc. Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2249644A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER

Also Published As

Publication number Publication date
WO2008097658A1 (en) 2008-08-14
MX2009008487A (es) 2010-01-15
EP2109451A4 (en) 2012-12-19
CN101663040A (zh) 2010-03-03
US20130202690A1 (en) 2013-08-08
CA2677639A1 (en) 2008-08-14
KR20090109130A (ko) 2009-10-19
BRPI0806362A2 (pt) 2011-09-06
AU2008214199A1 (en) 2008-08-14
US20100062056A1 (en) 2010-03-11
RU2009133447A (ru) 2011-03-20
IL200261A0 (en) 2010-04-29
JP2010518088A (ja) 2010-05-27
EP2109451A1 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
US20100062056A1 (en) Encapsulated picoplatin
ES2529570T3 (es) Formulaciones multiparticuladas de pantoprazol
TWI827535B (zh) 乳酸鈣組成物及使用方法
HK1206267A1 (en) Stabilized picoplatin oral dosage form
ES2794018T3 (es) Composiciones sólidas que comprenden un activador de la glucoquinasa y métodos para crearlas y usarlas
US20150196494A1 (en) Stabilized picoplatin oral dosage form
ES2744406T3 (es) Composiciones farmacéuticas para el tratamiento de helicobacter pylori
CN103037852A (zh) 苯达莫司汀的口服剂型及其治疗用途
PT686034E (pt) Forma de dosagem de bisacodil
US20240189234A1 (en) Silicon particles for drug delivery
CA3225480A1 (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
ES2753435T3 (es) Composición farmacéutica que comprende capecitabina y ciclofosfamida
KR20100101112A (ko) 경구 분립상 항종양제
CN102342931A (zh) 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
US20120148661A1 (en) High bioavailability oral picoplatin anti-cancer therapy
WO2005011737A2 (en) Pharmaceutical combinations and formulations with improved stability
ES2733113T3 (es) Composición farmacéutica estable de una sal de vinorelbina soluble en agua
HK1140131A (en) Stabilized picoplatin oral dosage form
JPH10226644A (ja) 医薬組成物
KR100505898B1 (ko) 철분함유 고밀도 펠렛 조성물 및 이의 제조방법
WO2025068971A1 (en) Compositions containing cabazitaxel and lipids for oral administration
RU2613146C1 (ru) Желатиновая капсула избирательного разрушения сосудов в опухолях
JP2023503842A (ja) がんを処置するための小児用製剤
US20030044459A1 (en) Biomodulated multiparticulate formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151022

Application number text: 1020097018781

Filing date: 20090908

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151120

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151202

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20170823

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171115

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170823

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20151202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I